Racetam · Russian Stimulant Nootropic

Phenylpiracetam: Phenylated Russian Racetam (Phenotropil / Carphedon)

A UK-focused, evidence-based comparison of Phenylpiracetam and Dihexa — mechanism, benefits, dosing, side effects, legal status, and stacking.

Phenylpiracetam (also known as Phenotropil, Phenylpiratsetam, Carphedon) is a Russian-developed racetam-class nootropic created in the 1980s for the Soviet space programme. It is the parent racetam piracetam with an added phenyl group, a structural modification that confers blood-brain barrier penetration far greater than piracetam and a distinctly stimulant-flavoured cognitive enhancement profile. It is registered as a prescription medicine in Russia and a small number of CIS markets for cerebrovascular disease, post-stroke recovery, and asthenic disorders. Its stimulant profile and WADA-banned status reflect its potency relative to other racetams — a far more pharmacologically "active" molecule than piracetam itself.

What is Phenylpiracetam?

Phenylpiracetam (chemical name 4-phenyl-2-pyrrolidinone-acetamide, also written 4-phenylpiracetam) is the parent compound piracetam with a phenyl ring added to the pyrrolidone, dramatically increasing lipophilicity and blood-brain barrier penetration. It is sold under the brand name Phenotropil in Russia (100 mg tablets), and as research-chemical powder internationally. There are also small clinical literature programmes around the methylated analogue Carphedon (essentially the same compound). The compound was famously included on the WADA Prohibited List after being detected in Olympic athletes from former Soviet states in the 2000s, and has been associated with several high-profile sport doping cases.

Chemistry: 4-phenyl-2-pyrrolidinone-acetamide · MW 218.25 g/mol · phenylated piracetam
Origin: Soviet space programme / Institute of Biomedical Problems, 1980s
Primary route: Oral (tablets or powder)
Pharmacokinetics: Plasma half-life 3-5 hours; functional cognitive and stimulant effects 4-6 hours per dose.
Class: Racetam · Stimulant cognitive enhancer

Mechanism of Action

Phenylpiracetam shares the core racetam mechanism — positive allosteric modulation of AMPA glutamate receptors with secondary effects on the cholinergic system — but the added phenyl group introduces additional pharmacology including: partial dopamine reuptake inhibition (the stimulant component, not present in other racetams), increased density of acetylcholine, NMDA and GABA-A receptors in the cortex following multi-week dosing, increased noradrenaline activity, and the same broad neuroprotective / antioxidant profile as the racetam family. The dopaminergic component is the key differentiator — phenylpiracetam feels stimulating in a way piracetam, aniracetam, and oxiracetam do not, and tolerance to the stimulant effect develops within days of consistent use (which is why intermittent dosing is universally recommended).

Proposed Benefits

Reported benefits include: significant acute cognitive performance enhancement on attention, working memory, and reaction time tasks within 30-60 minutes of dosing; physical performance enhancement (the reason for the WADA ban — phenylpiracetam improves endurance and reaction time in athletic contexts); improved cold tolerance (the originating Soviet space programme research context); mood lift often described as similar to a mild stimulant; improved memory consolidation over multi-week courses (the broader racetam BDNF/NGF effect). In Russian clinical practice phenylpiracetam is used for post-stroke cognitive recovery, ischaemic cerebrovascular disease, asthenic disorders, and depression with prominent fatigue. For healthy users the typical experience is a noticeable cognitive and physical performance lift that develops tolerance rapidly with daily use, making intermittent dosing the standard protocol.

Evidence Base

The evidence base is moderate in size and concentrated in Russian literature. Key references: Savchenko et al. 2005 (post-stroke recovery trial); Kalinsky and Nazarenko 2007 (asthenic disorder trial); various Soviet-era pharmacological characterisations; Wegener and Spurgeon 2008 (review of phenylpiracetam pharmacology). Russian Phase 3 trials support the registered indications (post-stroke, asthenia) with modest effect sizes. Independent Western replication is limited. Cognitive enhancement in healthy adults is supported by anecdotal reports and small studies but not by Western Phase 2+ trials. The compound's WADA inclusion is based on documented performance-enhancing effects in athletic contexts and a number of positive test results in Olympic-level athletes.

Dosage & Administration

Russian approved dose: 100-200 mg orally 1-2 times per day for 30-60 day courses. Community nootropic protocols: typically 100-200 mg taken once in the morning on demanding cognitive or training days, with intermittent rather than daily use due to rapid tolerance development. Most users find 100 mg sufficient and 200 mg over-stimulating. Effects begin within 30-60 minutes and last 4-6 hours. Tolerance: the stimulant effect of phenylpiracetam diminishes substantially after 3-5 consecutive days of use; most users dose only on demanding days (2-3 times per week maximum) to preserve effect. Adding a choline source (Alpha-GPC, CDP-choline) is recommended to reduce the headache that some users experience.

This is a community-reported protocol summary, not a medical recommendation. There is no established human dose. Consult a qualified healthcare professional before using any research compound.

Side Effects & Risks

Reported side effects mirror other stimulants more than other racetams: occasional insomnia (if dosed late in the day), irritability or jitteriness, tachycardia (mild but noticeable in some users), elevated blood pressure (usually minor), headache (often cholinergic-depletion-related), occasional anxiety. The compound is not formally classified as addictive, but the dopaminergic component does carry some reinforcement potential and users sometimes develop psychological reliance on dosing for high-performance days. Contraindications: active cardiovascular disease, uncontrolled hypertension, history of panic disorder or anxiety disorder, active psychotic illness, pregnancy/breastfeeding. Drug interactions: avoid with MAOIs, approach combinations with stimulants carefully (additive cardiovascular and CNS stimulation), can amplify the effects of other racetams.

UK Legal Status

UK: phenylpiracetam is not a controlled substance under the Misuse of Drugs Act 1971, not licensed as a medicine by the MHRA, and its position under the Psychoactive Substances Act 2016 is similar to Noopept — debated, with most UK retailers having withdrawn it from sale after 2016. WADA: phenylpiracetam (under the name carphedon) has been on the WADA Prohibited List since 2003 — banned in and out of competition. US: not FDA-approved; sold as research chemical with similar regulatory uncertainty to other Russian racetams. Russia: registered prescription medicine (Phenotropil) for documented neurological indications.

Phenylpiracetam vs Dihexa

Phenylpiracetam and Dihexa share a cognitive-enhancement positioning but with very different mechanisms and time courses. Phenylpiracetam is an acute stimulant-flavoured cognitive enhancer with effects within 30-60 minutes lasting 4-6 hours, plus modest cumulative racetam-class benefits over multi-week courses; tolerance develops rapidly with daily use. Dihexa is a non-stimulant structural synaptogenic peptide with effects building over weeks and persisting after the molecule clears. The two are mechanistically orthogonal — AMPA modulation plus dopamine reuptake inhibition versus direct HGF/c-Met activation. They could stack without competition. Phenylpiracetam is the more acutely felt of the two; Dihexa is the more structurally sustained.

Stacking with Dihexa

Phenylpiracetam is commonly stacked with: Alpha-GPC or CDP-choline (300 mg) to support cholinergic function and reduce headache, L-theanine to soften the stimulant edge, Noopept for combined glutamatergic / racetam cognitive enhancement (though both increase AMPA tone and may compound), and creatine for additional cognitive support. With Dihexa the rationale is acute racetam-class cognitive performance plus chronic synaptogenic structural plasticity. No published interaction data exists. Avoid stacking with MAOIs, with strong stimulants (caffeine in moderate doses is fine; avoid amphetamines), and with cardiac medications without medical guidance.

Frequently Asked Questions

Yes, substantially. Phenylpiracetam is active at 100-200 mg where piracetam is active at 800-4800 mg, and the phenyl modification adds dopamine reuptake inhibition that piracetam lacks, producing a noticeably stimulant cognitive effect.

Yes. Phenylpiracetam (carphedon) has been on the WADA Prohibited List since 2003 and is banned in and out of competition.

Tolerance develops rapidly to the dopaminergic stimulant component. Intermittent dosing (2-3 times per week maximum) preserves the effect; daily use produces tolerance within 3-5 days.

Not controlled, not licensed as a medicine, but the Psychoactive Substances Act 2016 position is ambiguous. Most UK retailers withdrew it from sale after 2016. Athletes subject to anti-doping should not use it.

No published interaction data exists. The mechanisms (AMPA + DAT inhibition vs HGF/c-Met activation) are non-competitive and the combination is mechanistically reasonable.

Phenotropil is the Russian brand name of phenylpiracetam (100 mg tablets) registered as a prescription medicine. They are the same compound.

The Bottom Line

Phenylpiracetam is the stimulant member of the racetam family, with documented acute cognitive and physical performance enhancement effects, but rapid tolerance development that limits daily use. Its WADA-banned status makes it unsuitable for any athlete subject to drug testing. Mechanistically distinct from Dihexa, phenylpiracetam offers acute performance support that Dihexa's structural plasticity does not directly provide. For non-athlete users seeking intermittent cognitive performance enhancement, phenylpiracetam is a reasonable Russian racetam choice with a longer track record than newer alternatives.